About
Acrivon AB develops targeted therapies for cancer patients by matching drug mechanisms to the biologic drivers of cancer using their proprietary AP3 platform. This platform uncovers drug sensitivity not achievable through genomics, enabling them to improve patient outcomes with their pipeline programs, including ACR-368, ACR-2316, and ACR-6840. Acrivon also partners with other companies to develop predictive OncoSignature tests for drug candidates.
Tags
Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does Acrivon AB do?
Acrivon AB develops targeted therapies for cancer patients by matching drug mechanisms to the biologic drivers of cancer using their proprietary AP3 platform. This platform uncovers drug sensitivity not achievable through genomics, enabling them to improve patient outcomes with their pipeline programs, including ACR-368, ACR-2316, and ACR-6840. Acrivon also partners with other companies to develop predictive OncoSignature tests for drug candidates.
How much funding has Acrivon AB raised?
Acrivon AB has raised a total of $10M in funding. The most recent round on record is Seed.
Where is Acrivon AB headquartered?
Acrivon AB is headquartered in Uppsala, Sweden.
When was Acrivon AB founded?
Acrivon AB was founded in 2022.
What industry does Acrivon AB operate in?
Acrivon AB operates in AI Tools & Apps, AI Drug Discovery, Biotech, HealthTech, Foundation Model, Generative AI.